Ignite Creation Date:
2024-05-06 @ 8:32 AM
Last Modification Date:
2024-10-26 @ 12:02 PM
Study NCT ID:
NCT02767804
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-09
First Post:
2016-04-30
Brief Title:
eXalt3 Study Comparing X-396 Ensartinib to Crizotinib in ALK Positive Non-Small Cell Lung Cancer NSCLC Patients
Sponsor:
Xcovery Holdings Inc
Organization:
Xcovery Holdings Inc
Organization Data
Organization:
Xcovery Holdings Inc
Class:
INDUSTRY
Study ID:
X396-CLI-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Xcovery Holdings Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None